抗炎症薬 - 世界市場の考察、競合情勢、市場予測（2030年）

世界の抗炎症薬の市場規模は、2024年～2030年の予測期間にCAGRで5.73%の成長が推定されています。抗炎症薬の需要は主に、喘息、関節炎、慢性閉塞性肺疾患（COPD）などのさまざまな慢性疾患の有病率の増加によって後押しされています。さらに、抗腫瘍壊死因子（TNF）、インターロイキン、ヤヌスキナーゼ阻害薬、抗炎症生物学的製剤、免疫選択的抗炎症誘導体（ImSAIDs）などに関する研究の増加、自己免疫疾患の有病率の上昇、バイオシミラー開発への注目の高まり、世界中での医薬品の上市と承認の増加などが、2024年～2030年の予測期間における抗炎症薬市場全体の成長に寄与しています。

抗炎症薬の市場力学

抗炎症薬市場はさまざまな要因によって製品需要が増加しており、その主な要因の1つは、世界中での慢性疼痛や炎症の負担の増加です。

米国疾病予防管理センター（CDC）（2020）によると、2019年に成人の20.4%が慢性疼痛を有し、成人の7.4%が過去3ヶ月間に生活や仕事の活動が頻繁に制限される慢性疼痛を有していました。また、慢性疼痛と高インパクト慢性疼痛はいずれも年齢とともに増加し、米国では65歳以上の成人でもっとも高いです。さらに、同資料によると、2019年に、非ヒスパニック系黒人（19.3％）、ヒスパニック系（13.0％）、非ヒスパニック系アジア人（6.8％）に比べ、非ヒスパニック系白人成人（23.6％）は慢性疼痛を抱える可能性が高いと思われます。

さらに、喘息はすべての年齢の人々に影響を与える慢性肺疾患です。気道周辺の炎症と筋肉の締め付けによって引き起こされ、呼吸がしにくくなります。例えば、世界保健機関（WHO）（2023）によると、喘息は2019年に推定2億6,200万人に影響を与え、4億5,500万人が死亡しています。

上記の資料によると、慢性疼痛と炎症性疾患の有病率は世界中で増加しており、副腎皮質ステロイドや非ステロイド性抗炎症薬などのさまざまな種類の抗炎症薬を使用して管理または治療することができます。

さらに、主要製薬企業はバイオシミラー関連の抗炎症薬の開発に注力しており、市場の拡大が見込まれています。また、主要な抗炎症性生物学的製剤の特許が切れることで、バイオシミラーが市場に参入する道が開かれました。需要の向上や、新薬よりもバイオシミラーのほうが承認プロセスが速いことから、複数のメーカーがこの分野に注目しています。このことが大きな市場動向となっています。アダリムマブ、インフリキシマブ、エタネルセプトのバイオシミラーは、ヒュミラ、レミケード、エンブレルの3つのバイオ医薬品と競合しています。

FDAは5種類のヒュミラのバイオシミラーを承認しており、そのすべてが2023年に米国で発売される予定です。アダリムマブのバイオシミラーについては、欧州などの他地域でも市販が開始されています。

さらに、まもなく独占権を失うリファレンス生物学的製剤のバイオシミラーを生み出すための臨床研究もすでに開始されています。今後数年間、抗炎症治療薬の需要が増加すると予測されます。

したがって、上記の要因が2024年～2030年の予測期間の抗炎症薬市場の成長に寄与しています。

しかし、薬剤に伴う副作用や厳格な規制手続きなどが、抗炎症薬市場の成長を抑制する可能性があります。

抗炎症薬市場のセグメント分析

抗炎症薬市場の適応症セグメントでは、関節炎カテゴリが2023年に大きな収益シェアを獲得すると予測されています。これは主に、世界中で関節炎の有病率が増加しているためです。また、このセグメントに関連する主要企業による発売の拡大や戦略的投資などの活動も、予測期間に市場を後押しする見込みです。

例えば、Global RA Network（2021）によると、2021年に世界で3億5,000万人以上が関節炎を患っています。さらに、世界保健機関（WHO）（2021）は、2021年に世界中で1,400万人以上が関節リウマチ（RA）を患っているとしています。さらに、Healio（2020）によると、2020年に世界中で4,200万人以上が痛風に罹患していると推定されています。

当レポートでは、世界の抗炎症薬市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 抗炎症薬市場レポートのイントロダクション

第2章 抗炎症薬市場のエグゼクティブサマリー

• 調査範囲
• 市場の概要
• 競合の評価

第3章 規制分析

• 米国
• 欧州
• 日本
• 中国

第4章 抗炎症薬市場の主な要因の分析

• 抗炎症薬市場の促進要因
• 抗炎症薬市場の抑制要因と課題
• 抗炎症薬市場の機会

第5章 抗炎症薬市場のポーターのファイブフォース分析

第6章 抗炎症薬市場のレイアウト

• 薬剤クラス別
  • 抗炎症性生物学的製剤
  • 非ステロイド性抗炎症薬（NSAID）
  • 免疫選択的抗炎症性誘導体（ImSAID）
  • コルチコステロイド
  • その他
• 適応症別
  • 関節炎
  • 喘息
  • 炎症性腸疾患（IBD）
  • 慢性閉塞性肺疾患（COPD）
  • 多発性硬化症
• 販売チャネル別
  • 処方
  • OTC
• 地域
  • 北米の抗炎症薬の市場規模（2021年～2030年）
  • 欧州の抗炎症薬の市場規模（2021年～2030年）
  • アジア太平洋の抗炎症薬の市場規模（2021年～2030年）
  • その他の地域の抗炎症薬の市場規模（2021年～2030年）

第7章 抗炎症薬市場の企業と製品のプロファイル

• Amgen Inc.
• Sun Pharmaceutical Industries Ltd.
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Medical Device Business Services, Inc.
• Novartis AG
• GSK plc.
• F. Hoffmann-La Roche Ltd
• AbbVie Inc.
• AstraZeneca
• Merck & Co., Inc.
• Lilly.
• Bristol-Myers Squibb Company
• Biogen
• Aurobindo Pharma
• Reckitt Benckiser Group PLC.
• Dr. Reddy's Laboratories Ltd.
• Sanofi
• Strides Pharma Science Limited
• Heron Therapeutics, Inc.

第8章 KOLの見解

第9章 プロジェクトのアプローチ

第10章 DelveInsightについて

第11章 免責事項、お問い合わせ

List of Tables

• Table 1: Competitive Analysis
• Table 2: Anti-Inflammatory Drugs Market in Global (2021-2030)
• Table 3: Anti-Inflammatory Drugs Market in Global by Drug Class (2021-2030)
• Table 4: Anti-Inflammatory Drugs Market in Global by Indication (2021-2030)
• Table 5: Anti-Inflammatory Drugs Market in Global by Sales Channel (2021-2030)
• Table 6: Anti-Inflammatory Drugs Market in Global by Geography (2021-2030)
• Table 7: Anti-Inflammatory Drugs Market in North America (2021-2030)
• Table 8: Anti-Inflammatory Drugs Market in the US (2021-2030)
• Table 9: Anti-Inflammatory Drugs Market in Canada (2021-2030)
• Table 10: Anti-Inflammatory Drugs Market in Mexico (2021-2030)
• Table 11: Anti-Inflammatory Drugs Market in Europe (2021-2030)
• Table 12: Anti-Inflammatory Drugs Market in France (2021-2030)
• Table 13: Anti-Inflammatory Drugs Market in Germany (2021-2030)
• Table 14: Anti-Inflammatory Drugs Market in the United Kingdom (2021-2030)
• Table 15: Anti-Inflammatory Drugs Market in Italy (2021-2030)
• Table 16: Anti-Inflammatory Drugs Market in Spain (2021-2030)
• Table 17: Anti-Inflammatory Drugs Market in the Rest of Europe (2021-2030)
• Table 18: Anti-Inflammatory Drugs Market in Asia-Pacific (2021-2030)
• Table 19: Anti-Inflammatory Drugs Market in China (2021-2030)
• Table 20: Anti-Inflammatory Drugs Market in Japan (2021-2030)
• Table 21: Anti-Inflammatory Drugs Market in India (2021-2030)
• Table 22: Anti-Inflammatory Drugs Market in Australia (2021-2030)
• Table 23: Anti-Inflammatory Drugs Market in South Korea (2021-2030)
• Table 24: Anti-Inflammatory Drugs Market in Rest of Asia-Pacific (2021-2030)
• Table 25: Anti-Inflammatory Drugs Market in the Rest of the World (2021-2030)
• Table 26: Anti-Inflammatory Drugs Market in the Middle East (2021-2030)
• Table 27: Anti-Inflammatory Drugs Market in Africa (2021-2030)
• Table 28: Anti-Inflammatory Drugs Market in South America (2021-2030)

List of Figures

• Figure 1: Competitive Analysis
• Figure 2: Anti-Inflammatory Drugs Market in Global (2021-2030)
• Figure 3: Anti-Inflammatory Drugs Market in Global by Drug Class (2021-2030)
• Figure 4: Anti-Inflammatory Drugs Market in Global by Indication (2021-2030)
• Figure 5: Anti-Inflammatory Drugs Market in Global by Sales Channel (2021-2030)
• Figure 6: Anti-Inflammatory Drugs Market in Global by Geography (2021-2030)
• Figure 7: Anti-Inflammatory Drugs Market in North America (2021-2030)
• Figure 9: Anti-Inflammatory Drugs Market in the US (2021-2030)
• Figure 10: Anti-Inflammatory Drugs Market in Canada (2021-2030)
• Figure 11: Anti-Inflammatory Drugs Market in Mexico (2021-2030)
• Figure 12: Anti-Inflammatory Drugs Market in Europe (2021-2030)
• Figure 13: Anti-Inflammatory Drugs Market in France (2021-2030)
• Figure 14: Anti-Inflammatory Drugs Market in Germany (2021-2030)
• Figure 15: Anti-Inflammatory Drugs Market in the United Kingdom (2021-2030)
• Figure 16: Anti-Inflammatory Drugs Market in Italy (2021-2030)
• Figure 17: Anti-Inflammatory Drugs Market in Spain (2021-2030)
• Figure 18: Anti-Inflammatory Drugs Market in the Rest of Europe (2021-2030)
• Figure 19: Anti-Inflammatory Drugs Market in Asia-Pacific (2021-2030)
• Figure 20: Anti-Inflammatory Drugs Market in China (2021-2030)
• Figure 21: Anti-Inflammatory Drugs Market in Japan (2021-2030)
• Figure 22: Anti-Inflammatory Drugs Market in India (2021-2030)
• Figure 23: Anti-Inflammatory Drugs Market in Australia (2021-2030)
• Figure 24: Anti-Inflammatory Drugs Market in South Korea (2021-2030)
• Figure 25: Anti-Inflammatory Drugs Market in Rest of Asia-Pacific (2021-2030)
• Figure 26: Anti-Inflammatory Drugs Market in the Rest of the World (2021-2030)
• Figure 27: Anti-Inflammatory Drugs Market in the Middle East (2021-2030)
• Figure 28: Anti-Inflammatory Drugs Market in Africa (2021-2030)
• Figure 29: Anti-Inflammatory Drugs Market in South America (2021-2030)
• Figure 30: Market Drivers
• Figure 31: Market Barriers
• Figure 32: Marker Opportunities
• Figure 33: PORTER'S Five Force Analysis

Anti-Inflammatory Drugs Market By Drug Class (Anti-Inflammatory Biologics, Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Immune-Selective Anti-Inflammatory Derivative (IMSAID), Corticosteroids, And Others), Indication (Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, And Others), Sales Channel (Prescription And Over The Counter (OTC)), and geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing burden of chronic pain and inflammation diseases such as migraine, arthritis, ophthalmic diseases, and others and the increasing research & developmental activities concerning to the anti-inflammatory drugs across the globe

The global anti-inflammatory drugs market is estimated to at a CAGR of 5.73% during the forecast period from 2024 to 2030. The demand for anti-inflammatory drugs is primarily being boosted by the increasing prevalence of various chronic diseases such as asthma, arthritis, chronic obstructive pulmonary disease (COPD), and other diseases. Further, the increasing research on anti-tumor necrosis factor (TNF), interleukins, Janus kinase inhibitors, anti-inflammatory biologics, immune selective anti-inflammatory derivatives (ImSAIDs), among others, the rising prevalence of auto-immune diseases, increasing focus on developing biosimilar, and the increasing drugs launches and approval across the globe among others are thereby contributing to the overall growth of the anti-inflammatory drugs market during the forecast period from 2024-2030.

Anti-Inflammatory Drugs Market Dynamics:

The anti-inflammatory drugs market is witnessing a growth in product demand owing to various factors, one of the key factors being the rising burden of chronic pain and inflammation across the globe.

According to the Centre for Disease Control and Prevention (CDC) 2020, in 2019, 20.4% of adults had chronic pain and 7.4% of adults had chronic pain that frequently limited life or work activities in the past 3 months. Also, chronic pain and high-impact chronic pain both increase with age and were highest among adults aged 65 and over, in the United States. Moreover, as per the same source, non-Hispanic white adults (23.6%) were more likely to have chronic pain compared with non-Hispanic black (19.3%), Hispanic (13.0%), and non-Hispanic Asian (6.8%) adults, in 2019.

Further, asthma is a chronic lung disease affecting people of all ages. It is caused by inflammation and muscle tightening around the airways, which makes it harder to breathe. For instance, as per the source World Health Organization (WHO) 2023, Asthma affected an estimated 262 million people in 2019 and caused 455 000 deaths.

The above source states that the prevalence of chronic pain and inflammatory diseases is increasing across the globe which can be managed or treated using various types of anti-inflammatory drugs such as corticosteroids and NSAIDs.

In addition, key pharmaceutical companies concentrating on creating biosimilar-related anti-inflammatory drugs are expected to expand the market. Also, the leading anti-inflammatory biologics' patents expiring paved the path for biosimilars to enter the market. Due to the rising demand and quicker approval process for biosimilars than for new drugs, several manufacturers have moved their attention to this area. This has grown to be a significant market trend. Adalimumab, infliximab, and etanercept biosimilars are competing against Humira, Remicade, and Enbrel, three biologics with considerable market revenue potential.

The FDA has approved five Humira biosimilars, all of which are anticipated to go on sale in the United States in 2023. While the adalimumab biosimilar is now commercially available in other areas, such as Europe.

Additionally, clinical research has already been started to create biosimilar versions of reference biologics that will soon lose their exclusivity. In the upcoming years, this is projected to increase the demand for anti-inflammatory treatments.

Therefore, the above-mentioned factors are contributing to the growth of the anti-inflammatory drugs market during the forecast period from 2024-2030.

However, side effects associated with drugs, stringent regulatory procedures, and others may restrict the anti-inflammatory drugs market growth.

Anti-Inflammatory Drugs Market Segment Analysis:

Anti-Inflammatory Drugs Market by Drug Class (Anti-Inflammatory Biologics, Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Immune-Selective Anti-Inflammatory Derivative (IMSAID), Corticosteroids, and Others), Indication (Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, and Others), Sales Channel (Prescription and Over the Counter (OTC)), and Geography (North America, Europe, Asia-Pacific, and the Rest of the World)

In the indication segment of the anti-inflammatory drugs market, the arthritis category is expected to amass a significant revenue share in the year 2023. This was primarily owing to the increasing prevalence of arthritis across the globe. Also, the expanding launches and strategic investments, and other activities by the key players related to the segment will support driving its market during the forecast period.

For instance, as per the Global RA Network 2021, more than 350 million people had arthritis, in 2021, globally. Further, the World Health Organization (WHO), 2021, more than 14 million people had rheumatoid arthritis (RA), in 2021, across the globe. Additionally, according to Healio, 2020, it was estimated that more than 42 million people around the world had gout, in 2020.

Non-steroidal anti-inflammatory medicines (NSAIDs), such as diclofenac, ibuprofen, and naproxen, a type of anti-inflammatory drugs are quite helpful at reducing osteoarthritis pain, but they also carry a risk of adverse effects such as stomach upset, and cardiovascular issues, blood issues, liver damage, and kidney damage. Thus, the above sources clearly state that the prevalence of different types of arthritis is quite high across the globe, ultimately leading to the increased demand for arthritis-managing anti-inflammatory drugs.

Further, the increasing product launches and approvals will also create a positive impact on segmental growth. For instance, in January 2022, AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa), a type of anti-inflammatory drugs for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts approximately 30 percent of patients with psoriasis.

Thus, the above-mentioned factors are likely to propel the demand for arthritis-treating anti-inflammatory drugs, thereby contributing to the growth of the anti-inflammatory drugs market during the forecast period from 2024-2030.

North America is expected to dominate the overall Anti-Inflammatory Drugs Market:

Among all the regions, North America is estimated to account for the largest share of the global anti-inflammatory drugs market in the year 2023. This domination is due to the increasing chronic pain and rising adoption of NSAIDs in headaches, migraine, toothaches, menstrual pain, and others, increasing launch and approvals of drugs by market players, established healthcare sector with a large number of renowned players, high investment & demand for more effective and safer drug, high income per capita, rise in patient visits to physicians, and research advancements due to high funding among others will propel the market of anti-inflammatory drugs in North America.

For instance, as per the study conducted by the Centre for Disease Control and Prevention (CDC) 2021, it was stated that in 2020, about one in four US adults, or about 58.5 million people were diagnosed with arthritis. By the year 2040, an estimated 78.4 million adults aged 18 years and older will be diagnosed with arthritis.

Further, as per the latest study done by Osteoarthritis (OA) Action Alliance, osteoarthritis (OA) is the most common form of arthritis, and affects nearly 32.5 million US adults, in 2020. The data analyzed from the source Arthritis Society Canada, 2021, stated that in 2021, nearly 6 million people were living with arthritis in Canada. The number to rise to 9 million in 2040.

Additionally, as per the Migraine Research Foundation (2023), migraine is a highly prevalent neurological disease, affecting nearly 40 million men, women, and children in the US while most sufferers experience attacks once or twice a month, more than 4 million people have chronic daily migraine, with at least 15 migraine days per month. Thus, the rising prevalence of chronic pain and inflammation-related disorders such as migraine, arthritis, and others will propel the demand for anti-inflammatory drugs during the forecast period.

Furthermore, the increasing activities by the key players in the region will in turn increase the demand for the product during the forecast period. For instance, in December 2021, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for XELJANZ® / XELJANZ® XR (tofacitinib), an anti-inflammatory drug for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.

Thus, all the above-mentioned factors will lead to an increase in the North America anti-inflammatory drugs market growth during the forecasting period of 2024-2030.

Anti-Inflammatory Drugs Market Key Players:

Some of the key market players operating in the anti-inflammatory drugs market include Amgen Inc., Sun Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Pfizer Inc., Medical Device Business Services, Inc., Novartis AG, GSK plc., F. Hoffmann-La Roche Ltd, AbbVie Inc., AstraZeneca, Merck & Co., Inc., Lilly., Bristol-Myers Squibb Company, Biogen, Aurobindo Pharma, Reckitt Benckiser Group PLC., Dr. Reddy's Laboratories Ltd., Sanofi, Strides Pharma Science Limited, Heron Therapeutics, Inc., and others.

Recent Developmental Activities in the Anti-Inflammatory Drugs Market:

In August 2022, Strides Pharma Global Pte Ltd received approval from the US health regulator for generic naproxen sodium soft gel capsules, used to treat pain or inflammation.

In August 2021, Alkem Labs announced the launch of Ibuprofen and Famotidine tablets in the U.S. after receiving approval from the U.S. FDA.

In November 2020, the Food and Drug Administration (FDA) issued an emergency use authorization for the anti-inflammatory drug baricitinib to treat COVID-19 in combination with anti-viral drug remdesivir.

Key Takeaways from the Anti-Inflammatory Drugs Market Report Study

Market size analysis for current anti-inflammatory drugs market size (2023), and market forecast for 5 years (2024-2030)

Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years

Key companies dominating the global anti-inflammatory drugs market.

Various opportunities available for the other competitor in the anti-inflammatory drugs market space.

What are the top-performing segments in 2023? How these segments will perform in 2030.

Which are the top-performing regions and countries in the current anti-inflammatory drugs market scenario?

Which are the regions and countries where companies should have concentrated on opportunities for anti-inflammatory drugs market growth in the coming future?

Target Audience who can be benefited from this Anti-Inflammatory Drugs Market Report Study

Anti-inflammatory drugs products providers

Research organizations and consulting companies

Anti-inflammatory drugs-related organizations, associations, forums, and other alliances

Government and corporate offices

Start-up companies, venture capitalists, and private equity firms

Distributors and Traders dealing in anti-inflammatory drugs

Various End-users who want to know more about the anti-inflammatory drugs market and the latest technological developments in the anti-inflammatory drugs market.

Frequently Asked Questions for the Anti-Inflammatory Drugs Market:

1. What are anti-inflammatory drugs?

Bone void filler is a medical device, intended to fill bony voids or gaps caused by trauma or surgery that are not intrinsic to the stability of the bony structure.

2. What is the market for global anti-inflammatory drugs?

The global anti-inflammatory drugs market is estimated to at a CAGR of 5.73% during the forecast period from 2024 to 2030.

3. What are the drivers for the global anti-inflammatory drugs market?

The demand for anti-inflammatory drugs is primarily being heightened by the growing burden of chronic pain and inflammation such as arthritis, and migraine, among others, the increasing geriatric population base prone to chronic pain, the emergence of anti-inflammatory biologics, and increasing drugs launches and approvals, among others, thereby contribute to the overall growth of the anti-inflammatory drugs market during the forecast period from 2024-2030.

4. Who are the key players operating in the global anti-inflammatory drugs market?

Some of the key market players operating in the anti-inflammatory drugs market include Amgen Inc., Sun Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Pfizer Inc., Medical Device Business Services, Inc., Novartis AG, GSK plc., F. Hoffmann-La Roche Ltd, AbbVie Inc., AstraZeneca, Merck & Co., Inc., Lilly., Bristol-Myers Squibb Company, Biogen, Aurobindo Pharma, Reckitt Benckiser Group PLC., Dr. Reddy's Laboratories Ltd., Sanofi, Strides Pharma Science Limited, Heron Therapeutics, Inc., and others.

5. Which region has the highest share in the anti-inflammatory drugs market?

North America is expected to dominate the overall anti-inflammatory drugs market during the forecast period from 2024-2030. Factors such as the increasing demand for anti-inflammatory biologics, government support for the launch of biosimilars, significant research investment, increased, presence of favorable regulatory authorities, rising product launch and approvals, and the presence of key players in the region, among others will positively impact the North American anti-inflammatory drugs market.

Table of Contents

1. Anti-Inflammatory Drugs Market Report Introduction

2. Anti-Inflammatory Drugs Market Executive Summary

• 2.1. Scope of the Study
• 2.2. Market at Glance
• 2.3. Competitive Assessment

3. Regulatory Analysis

• 3.1. The United States
• 3.2. Europe
• 3.3. Japan
• 3.4. China

4. Anti-Inflammatory Drugs Market Key Factors Analysis

• 4.1. Anti-Inflammatory Drugs Market Drivers
  • 4.1.1. The growing burden of chronic pain and inflammation
  • 4.1.2. Increasing geriatric population base prone to chronic pain
  • 4.1.3. Rising adoption of anti-inflammatory biologics
• 4.2. Anti-Inflammatory Drugs Market Restraints and Challenges
  • 4.2.1. Side effects associated with drugs
  • 4.2.2. Stringent regulatory procedure
• 4.3. Anti-Inflammatory Drugs Market Opportunities
  • 4.3.1. Availability of a robust product portfolio
  • 4.3.2. Increasing focus on developing biosimilars by key pharmaceutical companies

5. Anti-Inflammatory Drugs Market Porter's Five Forces Analysis

• 5.1. Bargaining Power of Suppliers
• 5.2. Bargaining Power of Consumers
• 5.3. Threat of New Entrants
• 5.4. Threat of Substitutes
• 5.5. Competitive Rivalry

6. Anti-Inflammatory Drugs Market Layout

• 6.1. By Drug Class
  • 6.1.1. Anti-Inflammatory Biologics
  • 6.1.2. Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • 6.1.3. Immune-selective anti-inflammatory derivative (ImSAID)
  • 6.1.4. Corticosteroids
  • 6.1.5. Others
• 6.2. By Indication
  • 6.2.1. Arthritis
  • 6.2.2. Asthma
  • 6.2.3. Inflammatory bowel disease (IBD)
  • 6.2.4. Chronic obstructive pulmonary disease (COPD)
  • 6.2.5. Multiple Sclerosis
  • 6.2.6. Others
• 6.3. By Sales Channel
  • 6.3.1. Prescription
  • 6.3.2. Over the Counter (OTC)
• 6.4. By Geography
  • 6.4.1. North America Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.1.1. United States Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.1.2. Canada Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.1.3. Mexico Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
  • 6.4.2. Europe Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.2.1. France Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.2.2. Germany Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.2.3. United Kingdom Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.2.4. Italy Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.2.5. Spain Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.2.6. Rest of Europe Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
  • 6.4.3. Asia-Pacific Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.3.1. China Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.3.2. Japan Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.3.3. India Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.3.4. Australia Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.3.5. South Korea Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.3.6. Rest of the Asia-Pacific Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
  • 6.4.4. Rest of the World (RoW) Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.4.1. Middle East Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.4.2. Africa Anti-Inflammatory Drugs Market Size in USD million (2021-2030)
    • 6.4.4.3. South America Anti-Inflammatory Drugs Market Size in USD million (2021-2030)

7. Anti-Inflammatory Drugs Market Company and Product Profiles

• 7.1. Amgen Inc.
  • 7.1.1. Company Overview
  • 7.1.2. Company Snapshot
  • 7.1.3. Financial Overview
  • 7.1.4. Product Listing
  • 7.1.5. Entropy
• 7.2. Sun Pharmaceutical Industries Ltd.
  • 7.2.1. Company Overview
  • 7.2.2. Company Snapshot
  • 7.2.3. Financial Overview
  • 7.2.4. Product Listing
  • 7.2.5. Entropy
• 7.3. Johnson & Johnson Services, Inc.
  • 7.3.1. Company Overview
  • 7.3.2. Company Snapshot
  • 7.3.3. Financial Overview
  • 7.3.4. Product Listing
  • 7.3.5. Entropy
• 7.4. Pfizer Inc.
  • 7.4.1. Company Overview
  • 7.4.2. Company Snapshot
  • 7.4.3. Financial Overview
  • 7.4.4. Product Listing
  • 7.4.5. Entropy
• 7.5. Medical Device Business Services, Inc.
  • 7.5.1. Company Overview
  • 7.5.2. Company Snapshot
  • 7.5.3. Financial Overview
  • 7.5.4. Product Listing
  • 7.5.5. Entropy
• 7.6. Novartis AG
  • 7.6.1. Company Overview
  • 7.6.2. Company Snapshot
  • 7.6.3. Financial Overview
  • 7.6.4. Product Listing
  • 7.6.5. Entropy
• 7.7. GSK plc.
  • 7.7.1. Company Overview
  • 7.7.2. Company Snapshot
  • 7.7.3. Financial Overview
  • 7.7.4. Product Listing
  • 7.7.5. Entropy
• 7.8. F. Hoffmann-La Roche Ltd
  • 7.8.1. Company Overview
  • 7.8.2. Company Snapshot
  • 7.8.3. Financial Overview
  • 7.8.4. Product Listing
  • 7.8.5. Entropy
• 7.9. AbbVie Inc.
  • 7.9.1. Company Overview
  • 7.9.2. Company Snapshot
  • 7.9.3. Financial Overview
  • 7.9.4. Product Listing
  • 7.9.5. Entropy
• 7.10. AstraZeneca
  • 7.10.1. Company Overview
  • 7.10.2. Company Snapshot
  • 7.10.3. Financial Overview
  • 7.10.4. Product Listing
  • 7.10.5. Entropy
• 7.11. Merck & Co., Inc.
  • 7.11.1. Company Overview
  • 7.11.2. Company Snapshot
  • 7.11.3. Financial Overview
  • 7.11.4. Product Listing
  • 7.11.5. Entropy
• 7.12. Lilly.
  • 7.12.1. Company Overview
  • 7.12.2. Company Snapshot
  • 7.12.3. Financial Overview
  • 7.12.4. Product Listing
  • 7.12.5. Entropy
• 7.13. Bristol-Myers Squibb Company
  • 7.13.1. Company Overview
  • 7.13.2. Company Snapshot
  • 7.13.3. Financial Overview
  • 7.13.4. Product Listing
  • 7.13.5. Entropy
• 7.14. Biogen
  • 7.14.1. Company Overview
  • 7.14.2. Company Snapshot
  • 7.14.3. Financial Overview
  • 7.14.4. Product Listing
  • 7.14.5. Entropy
• 7.15. Aurobindo Pharma
  • 7.15.1. Company Overview
  • 7.15.2. Company Snapshot
  • 7.15.3. Financial Overview
  • 7.15.4. Product Listing
  • 7.15.5. Entropy
• 7.16. Reckitt Benckiser Group PLC.
  • 7.16.1. Company Overview
  • 7.16.2. Company Snapshot
  • 7.16.3. Financial Overview
  • 7.16.4. Product Listing
  • 7.16.5. Entropy
• 7.17. Dr. Reddy's Laboratories Ltd.
  • 7.17.1. Company Overview
  • 7.17.2. Company Snapshot
  • 7.17.3. Financial Overview
  • 7.17.4. Product Listing
  • 7.17.5. Entropy
• 7.18. Sanofi
  • 7.18.1. Company Overview
  • 7.18.2. Company Snapshot
  • 7.18.3. Financial Overview
  • 7.18.4. Product Listing
  • 7.18.5. Entropy
• 7.19. Strides Pharma Science Limited
  • 7.19.1. Company Overview
  • 7.19.2. Company Snapshot
  • 7.19.3. Financial Overview
  • 7.19.4. Product Listing
  • 7.19.5. Entropy
• 7.20. Heron Therapeutics, Inc.
  • 7.20.1. Company Overview
  • 7.20.2. Company Snapshot
  • 7.20.3. Financial Overview
  • 7.20.4. Product Listing
  • 7.20.5. Entropy

8. KOL Views

9. Project Approach

10. About DelveInsight

11. Disclaimer & Contact Us